XORTX Highlights New Gout Genetics Research, Reshapes Board and Clarifies Financing as Vectus Deal Nears Closing

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialThe latest announcement is out from XORTX Therapeutics Inc ( (TSE:XRTX) ). On December 31, 2025, XORTX Therapeutics highlighted newly published, independent genome-wide research showing more than 400 genetic factors associated with urate levels and gout, and broader links between xanthine oxidase over-expression and conditions such as hyperuricemia, chronic kidney disease, sepsis-related organ failure, diabetes, polycystic kidney disease, and kidney failure. The company said these findings reinforce its strategy of pharmacologically inhibiting xanthine oxidase and support a precision medicine model in which genetic risk variants guide treatment, positioning its oxypurinol-based gout program and broader XO-inhibitor platform as potentially well aligned with emerging scientific evidence and future regulatory filings. The company also announced several corporate developments dated December 31, 2025, including the appointment of biotechnology executive Krysta Davies Foss to its board and the resignation of three directors, reducing the board to five members. XORTX corrected prior disclosure on its October 29, 2025 US$1.1 million registered direct offering, clarifying the exact mix of common shares, pre-funded warrants, and the associated commission paid to its placement agent, which may be of interest to existing and prospective shareholders tracking dilution and capital structure. In addition, XORTX updated the market on its planned acquisition of Vectus Biosystems’ renal anti-fibrotic therapeutic program, noting that closing, targeted by January 13, 2026 under the binding term sheet, is pending Australian Securities Exchange guidance on whether Vectus must seek shareholder approval, a process that could influence the timing but not the parties’ stated commitment to complete the transaction. The most recent analyst rating on (TSE:XRTX) stock is a Hold with a C$0.81 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page. Spark’s Take on TSE:XRTX Stock According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Neutral. The score is primarily constrained by weak financial fundamentals (no revenue, ongoing losses and cash burn, shrinking equity base) alongside a broadly weak technical trend (below key moving averages with negative MACD). Recent corporate actions are modest positives (capital raise and pipeline acquisition) but do not fully offset the reliance on external financing and dilution risk. To see Spark’s full report on TSE:XRTX stock, click here. More about XORTX Therapeutics Inc XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies that target aberrant purine metabolism and xanthine oxidase to reduce uric acid production. Its pipeline includes three clinically advanced programs: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney and organ injury associated with respiratory virus infections, as well as a preclinical program, XRx-225, for Type 2 diabetic nephropathy. The company aims to improve outcomes for patients with gout, progressive kidney disease, and related conditions through precision, XO-inhibitor-based treatments. Average Trading Volume: 21,081 Technical Sentiment Signal: Strong Sell Current Market Cap: C$5.53M For a thorough assessment of XRTX stock, go to TipRanks’ Stock Analysis page.